Literature DB >> 1335184

Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.

S Yei1, M W Yu, D L Tankersley.   

Abstract

Because of concern about the safety of immune globulins with respect to transmission of hepatitis C, the partitioning of hepatitis C virus (HCV) during alcohol fractionation of a plasma pool prepared exclusively from anti-HCV-reactive donations was examined. Quantitation of HCV RNA was accomplished by nested polymerase chain reaction (PCR) at limiting dilutions. One PCR unit was arbitrarily defined as the minimum amount of HCV RNA from which an amplified product could be detected. The starting plasma pool contained 1.4 x 10(5) PCR units per mL. Most of the HCV RNA was found in cryoprecipitate and in Cohn fractions I and III, but it was also detected in fraction II, which is used for immunoglobulin G preparations. A 3.4-percent solution of IgG prepared from this fraction II contained 30 PCR units per mL. The fractionation process leading to immune globulin resulted in overall reduction in HCV RNA by a factor of 4.7 x 10(4). Although the presence of HCV RNA in the final product does not necessarily imply the presence of infectious virus, this work suggests that the safety of immune globulins with respect to HCV transmission is not due solely to the partitioning of HCV away from the immunoglobulin fraction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335184     DOI: 10.1046/j.1537-2995.1992.32993110753.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

Review 1.  Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.

Authors:  H M Chapel
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

2.  Infection with hepatitis C virus. Intravenous gammaglobulin may still infect patients.

Authors:  I Quinti; G Sacco; D el Salman; R Paganelli; M Fiorilli; F Aiuti; F Pandolfi
Journal:  BMJ       Date:  1994-03-26

Review 3.  Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

Authors:  H B Slade
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

4.  Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma.

Authors:  Mei-ying W Yu; Birke Bartosch; Pei Zhang; Zheng-ping Guo; Paula M Renzi; Li-Ming Shen; Christelle Granier; Stephen M Feinstone; François-Loïc Cosset; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

Review 5.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

6.  Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Authors:  Richard L Wasserman; Joseph A Church; Mark Stein; James Moy; Martha White; Steven Strausbaugh; Harry Schroeder; Mark Ballow; James Harris; Isaac Melamed; David Elkayam; William Lumry; Daniel Suez; Syed M Rehman
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

7.  A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.

Authors:  Zhong Zhao; Lilin Zhong; Elizabeth Elrod; Evi Struble; Li Ma; Hailing Yan; Christine Harman; Lu Deng; Maria Luisa Virata-Theimer; Peter Liu; Harvey Alter; Arash Grakoui; Pei Zhang
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

Review 8.  Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacy.

Authors:  Albert Farrugia; Isabella Quinti
Journal:  Front Immunol       Date:  2014-12-23       Impact factor: 7.561

Review 9.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

10.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.